3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
Cyclophosphamide
27
fludarabine
19
Dexamethasone
18
pembrolizumab
12
Rituximab
12
Etoposide
11
venetoclax
10
pomalidomide
9
Gemcitabine
9
Lenalidomide
8
fludarabine phosphate
7
daratumumab
7
Bortezomib
7
glofitamab
6
carfilzomib
6
Vincristine
6
obinutuzumab
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Doxorubicin
5
Cytarabine
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Carboplatin
4
Azacitidine
4
zanubrutinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
ficlatuzumab
×
90 days
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled